EZH2 as a potential target for NAFLD therapy

Cited 6 time in scopus
Metadata Downloads
Title
EZH2 as a potential target for NAFLD therapy
Author(s)
Hyunjung Lim; Mi Rang Kim
Bibliographic Citation
International Journal of Molecular Sciences, vol. 21, no. 22, pp. 8617-8617
Publication Year
2020
Abstract
Non-alcoholic fatty liver disease (NAFLD) is a complex disease that is affected by genetic predisposition and epigenetic modification. Deregulation of epigenetic pathways is now recognized as a frequent event in NAFLD, and understanding the mechanistic roles of these epigenetic factors may lead to new strategies for NAFLD treatment. Enhancer of zeste homolog 2 (EZH2) catalyzes methylation on Lys 27 of histone H3, which leads to chromatin compaction and gene silencing. EZH2 regulates embryonic development and cell lineage determination and is related to many human diseases. Recent studies show that EZH2 has critical roles in liver development, homeostasis, and regeneration. Moreover, aberrant activation of EZH2 promotes NAFLD progression. Several EZH2 inhibitors have been developed and studied both in vitro and in clinical trials. In this review, we summarize our current understanding of the role of EZH2 in NAFLD and highlight its potential as a novel therapeutic target for NAFLD treatment.
Keyword
epigeneticsEZH2NAFLDNASHliver fibrosis
ISSN
1661-6596
Publisher
MDPI
DOI
http://dx.doi.org/10.3390/ijms21228617
Type
Article
Appears in Collections:
Aging Convergence Research Center > 1. Journal Articles
Files in This Item:
  • There are no files associated with this item.


Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.